Question to the Department of Health and Social Care:

To ask the Secretary of State for Health, for what reasons the Lutathera drug was removed from the list of drugs available under the Cancer Drugs Fund.

Peptide receptor radionuclide therapy (including Luththera) for the treatment of gastro-entero-pancreatic neuroendocrine tumours was removed from the Cancer Drugs Fund in November 2015 on the grounds that it represented insufficient value for retention within the Fund.

NHS England’s full decision summary is available at:

https://www.england.nhs.uk/ourwork/cancer/cdf/cdf-drug-sum/